Browsing by Author "Osório, L."
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- mHealth in Urology: A Review of Experts' Involvement in App DevelopmentPublication . Pereira-Azevedo, N.; Carrasquinho, E.; Cardoso-Oliveira, E.; Cavadas, V.; Osório, L.; Fraga, A.; Castelo-Branco, M.; Roobol, M.Smartphones are increasingly playing a role in healthcare and previous studies assessing medical applications (apps) have raised concerns about lack of expert involvement and low content accuracy. However, there are no such studies in Urology. We reviewed Urology apps with the aim of assessing the level of participation of healthcare professionals (HCP) and scientific Urology associations in their development.
- NEFRECTOMIA PARCIAL – A EXPERIÊNCIA DE 10 ANOS DO HOSPITAL DE SANTO ANTÓNIOPublication . Oliveira, M.; Vila, F.; Osório, L.; Cavadas, V.; Teves, F.; Branco, F.; Almeida, F.; Fernandes, J.; Ramires, R.; Marcelo, F.A nefrectomia parcial (NP) é uma técnica reconhecida no tratamento de diferentes patologias renais,nomedamente na oncológica. Os autores apresentam a sua casuística dos últimos 10 anos, com avaliação dos índices de recorrência e sobrevivência.
- Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone AppPublication . Pereira-Azevedo, N.; Osório, L.; Fraga, A.; Roobol, M.BACKGROUND: The use of prostate cancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostate cancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both practitioners and patients for a variety of purposes. OBJECTIVE: The impetus of the study was to design, develop, and assess a smartphone app for prostate cancer screening, based on the Rotterdam Prostate Cancer Risk Calculator (RPCRC). METHODS: The results of the Rotterdam arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC) study were used to elaborate several algorithms that allowed the risk of prostate cancer to be estimated. A step-by-step workflow was established to ensure that depending on the available clinical information the most complete risk model of the RPCRC was used. The user interface was designed and then the app was developed as a native app for iOS. The usability of the app was assessed using the Post-Study System Usability Questionnaire (PSSUQ) developed by IBM, in a group of 92 participants comprising urologists, general practitioners, and medical students. RESULTS: A total of 11 questions were built into the app, and, depending on the answers, one of the different algorithms of the RPCRC could be used to predict the risk of prostate cancer and of clinically significant prostate cancer (Gleason score ≥7 and clinical stage >T2b). The system usefulness, information quality, and interface quality scores were high-92% (27.7/30), 87% (26.2/30), and 89% (13.4/15), respectively. No usability problems were identified. CONCLUSIONS: The RPCRC app is helpful in predicting the risk of prostate cancer and, even more importantly, clinically significant prostate cancer. Its algorithms have been externally validated before and the usability score shows the app's interface is well designed. Further usability testing is required in different populations to verify these results and ensure that it is easy to use, to warrant a broad appeal, and to provide better patient care.